Review Article
Volume 11 Issue 3 - 2020
Endocannabinoids in Orthopedic Surgery and Musculoskeletal Medicine: Is it Time for a Green Standard?
Austin Yeargan III1*, Brittany Larussa1, Brandy Wians1, Bailey E Montgomery2 and William Montgomery Jr1
1Regenerative Medicine Clinic, Wilmington, NC, USA
2Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
*Corresponding Author: Austin Yeargan III, Regenerative Medicine Clinic, Wilmington, NC, USA.
Received: January 04, 2020; Published: February 19, 2020


Cannabis and endocannabinoid agonists have been safely used for decades by a large segment of the United States population for both recreational and medicinal purposes [1]. The medical use of cannabis products has been legislatively restricted for decades in the United States [2]. Due to widespread enthusiasm for cannabis in American Society, no authority can deny the wide margin of safety that exists, even for chronic use [3,4]. Newly enacted legislation over the last several years has decriminalized cannabis consumption and even legalized its use in some states for both recreation and medicinal purposes [5]. Most recently, clinicians’ guides to cannabidiol (CBD) and hemp oils have moved to the front seat of many prestigious clinical publications [6]. The translation of cannabinoids from herbal preparations into highly regulated prescription drugs is progressing very rapidly and healthcare practitioners must become familiar with its mechanisms and possible clinical applications [7]. These drugs and supplements may provide an unmet need in the management of patients with osteoarthritis and other musculoskeletal ailments. It may be time for a new gold standard in our approach to the clinical condition of arthritis where these pharmaceuticals play an important role.

Keywords: Endocannabinoids; Orthopedic Surgery; Musculoskeletal Medicine; Cannabis


  1. Hutchinson KE., et al. “Cannabis and health research: Rapid progress requires innovative research designs”. Value Health 22.11 (2019): 1289-1294.
  2. Corroon J., et al. “Indications and administration practices amongst medical cannabis healthcare providers: a cross-sectional survey”. BMC Family Practice 14 20.1 (2019): 174.
  3. Zvonarev V., et al. “The public health concerns of marijuana legalization: An overview of current trends”. Cureus 30 11.9 (2019): e5806.
  4. Burns TL and Ineck JR. “Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain”. Annals of Pharmacotherapy 40.2 (2006): 251-260. 
  5. Meffert BN., et al. “Navigating blind in the green rush: Clinical considerations and harm reduction practices for cannabis”. Current Drug Abuse Reviews 1 (2019): 3-11.
  6. VanDolah HJ., et al. “Clinician’s guide to cannabidiol and hemp oils”. Mayo Clinic Proceedings 94.9 (2019): 1840-1851.
  7. Bruni N., et al. “Cannabinoid Delivery Systems for Pain and Inflammation Treatment”. Molecules 23.10 (2018): 2478. 
  8. Carliner H., et al. “Cannabis use, attitudes, and legal status in the U.S: A review”. Preventive Medicine 104 (2017): 13-23.
  9. Corroon J and Kight R. “Regulatory status of cannabidiol in the United States: A perspective”. Cannabis and Cannabinoid Research 27 3.1 (2018): 190-194.
  10. VanDolah H., et al. “Clinician’s Guide to Cannabidiol and Hemp Oils”. Mayo Clinic Proceedings 94.9 (2019): 1840-1851. 
  11. Herbst J and Musgrave. “Respiratory depression following an accidental overdose of a CBD-labeled product. A pediatric case report”. Journal of the American Pharmacists Association 60.1 (2019). 
  12. Media: ‘Start Low and Go Slow’ – 3 Steps to Safely Consume Marijuana Edibles.
  13. Chandra S., et al. “Cannabis Cultivation: Methodological issues for obtaining medical grade product”. Epilepsy and Behavior 70 (2017): 302-312.
  14. Grof CPL. “Cannabis, from Plant to Pill”. British Journal of Clinical Pharmacology 84.11 (2018): 2463-2467.
  15. Mead A. “The legal status of cannabis (marijuana) and cannabidiol under US law”. Epilepsy and Behavior 70 (2017): 288-291.
  16. White CM. “A review of human studies assessing Cannabidiol (CBD) therapeutic action and potential”. The Journal of Clinical Pharmacology 59.7 (2019): 923-934.
  17. Cogan PS. “On healthcare by popular appeal: Critical assessment of benefit and risk in cannabidiol based dietary supplements”. Expert Review of Clinical Pharmacology 12.6 (2019): 501-511.
  18. Karst Allison. “Weighing the Benefits and Risks of Medical Marijuana Use: A Brief Review”. Pharmacy (Basel, Switzerland), MDPI (2018).
  19. Singer L., et al. “The cannabidiol conundrum: potential benefits and risks of cannabidiol products for children”. Current Opinion in Pediatrics 10 (2019). 
  20. Bowling CM and Glantz SA. “Conflict of interest provisions in state laws governing medial and adult use cannabis”. American Journal of Public Health 109.3 (2019): 423-426. 
  21. Franco Vk Perucca E. “Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy”. Drugs 79.13 (2019): 1435-1454. 
  22. Pacher P., et al. “The endocannabinoid system as an emerging target of pharmacotherapy”. Pharmacological Reviews 58.3 (2006): 389-462.
  23. Wallace Alicia. “Patent No. 6,630,507: Why the U.S. Government Holds a Patent on Cannabis Plant Compounds”. The Denver Post, The Denver Post, 2 (2016). 
  24. Appendino G., et al. “Cannabinoids: occurrence and medicinal chemistry”. Current Medicinal Chemistry 18.7 (2011): 1085-1099.
  25. BenAmar M. “Cannabinoids in medicine: A review of their therapeutic potential”. Journal of Ethnopharmacology 105.1-2 (2006): 1-25.
  26. R Rappaport. “Cannabinoids may complement rehabilitation, joint or spinal injections’ in Orthopedics” (2019).
  27. S Chandra., et al. “Cannabis Sativa L.: Botany and Horticulture” (1970). 
  28. Crofford and Leslie J. “Use of NSAIDs in Treating Patients with Arthritis”. Arthritis Research and Therapy BioMed Central (2013). 
  29. Brune K. “Safety of anti-inflammatory treatment-New ways of thinking”. Rheumatology 43.1 (2004): i16-20.
  30. Wong Rebecca SY. “Disease-Modifying Effects of Long-Term and Continuous Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Spondyloarthritis”. Advances in Pharmacological Sciences 29 (2019). 
  31. Moore N., et al. “Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs”. Therapeutics and Clinical Risk Management 11 (2015): 1061–1075. 
  32. Gowdey CW and Brennan M. “A review of fatalities as associated with NSAID treatment in Ontario”. Canadian Family Physician 32 (1986): 1931-1934.
  33. McCarthy DM. “Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs”. Best Practice and Research: Clinical Gastroenterology 15.5 (2001): 755-773. 
  34. Sostres, Carlos., et al. “Nonsteroidal Anti-Inflammatory Drugs and Upper and Lower Gastrointestinal Mucosal Damage”. Arthritis Research and Therapy, BioMed Central (2013).
  35. Curtis Elizabeth., et al. “Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis”. Drugs and Aging, Springer International Publishing (2019). 
  36. Nissen SE., et al. “For the PRECISION Trial investigators. Cardiovascular safety of Celecoxib, Naproxen or Ibuprofen for arthritis”. The New England Journal of Medicine (2016): 2519-2529.
  37. Pundole X., et al. “Utilization of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer”. Clinical Rheumatology (2019). 
  38. Bonn-Miller MO., et al. “Labeling Accuracy of Cannabidiol extracts sold online”. Journal of the American Medicine Association 318.17 (2017): 1708-1709.
  39. Devane WA., et al. “Isolation and structure of a brain constituent that binds to the cannabinoid receptor”. Science 258.5090 (1992): 1946-1949.
  40. Kight R. “Cannabis, Health Care and Federal Law”. American Journal of Endocannabinoid Medicine 1.1 (2019): 8-10.
  41. “Physicians Explore Cannabinoids as Pain Management Solution”. Orthopedics Today 11 (2019): 10-12.
  42. P Nagarkatti., et al. “Cannabinoids as Novel Anti-Inflammatory Drugs”. Future Medicinal Chemistry 1.7 (2009): 1333-1349. 
  43. Russo EB and Marcu J. “Cannabis Pharmacology: the usual suspects and a few promising leads”. Advances in Pharmacology 80 (2017): 67-134. 
  44. Pacher P and Kunos G. “Modulating the Endocannbinoid System in Human Health and Disease-successes and failures”. The FEBS Journal 280.9 (2013): 1918-1943.
  45. MA Huestis ML Smith. “Cannabinoid Markers in Biological Fluids and Tissues: Revealing Intake”. Trends in Molecular Medicine (2017): S1471. 
  46. Pacifici R., et al. “Evaluation of cannabinoids concentration and stability in standardized preparation of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectroscopy”. Clinical Chemistry and Laboratory Medicine 28 55.10 (2017): 1555-1563.
  47. Marcu J. “The Biochemical System Controlling the Effects of Cannabis: An Introduction”. HerbalEGram (2015): 12.6.
Citation: Austin Yeargan III., et al. “Endocannabinoids in Orthopedic Surgery and Musculoskeletal Medicine: Is it Time for a Green Standard?”. EC Orthopaedics 11.3 (2020): 01-09.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

March Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the March issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before April 14, 2023.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.